英首相车内讲话未系安全带被罚款 苏纳克摊上大事...

BD公司生物科学系统全球总裁艾伯特·马斯（Alberto Mas）先生、BD公司生 导读：全国首个COE-卓越中心20日在中山医院举行了隆重的揭牌仪式。

礼来暂缓加薪计划 不涉及中国区域 2012-02-08 07:00 · lule 礼来中国有关负责人表示，网传礼来冻结员工2012年基本工资，存在本质性的错误。至今，我们在全国拥有四家独资企业，数十家办事机构，员工3800多人，在中国建立了自己的研究中心，并与中国科研机构联合进行合成化学研究。

虽然几经风雨，我们始终不能割舍中国情结，在1993年重新回到中国。据悉，目前，礼来公司的员工总数为3.8万人左右。礼来中国有关负责人表示，网传礼来冻结员工2012年基本工资，存在本质性的错误。礼来于1918年来到中国，将其第一个海外代表处设在上海，从而迈出了全球化的第一步。礼来公司在向美国证券交易委员会提交的文件中表示，该公司冻结2012年薪酬的决定将适用于全球范围内绝大多数国家的员工，其中也包括高管人员

2011年主要制药公司交易 2012-02-07 16:00 · 李华芸 This Deal Watch article focuses on a review of some of the trends we saw in transactions announced throughout 2011. Continuing the theme fr This Deal Watch article focuses on a review of some of the trends we saw in transactions announced throughout 2011. Continuing the theme from 2010 we saw many of the large companies addressing the need to find sources of differentiated new products, in addition to expanding into new areas such as biosimilars, generics and orphans. Interestingly and according to MedTrack data, in absolute numbers the number of deals (preclinical to pending approval) announced in 2011 was 4 per cent lower than in 2010. However, there were several deals with price tags of over $10bn. As predicted, mergers and acquisitions played a major role in continuing to change the pharmaceutical industry landscape during 2011. The rationale behind these transactions included the need to bolster flagging portfolios and buy into new therapeutic areas, as well as the extension of geographic reach. Some examples of MAs during 2011 are provided in table 1. There were some major acquisitions during the year, and one of the largest was JJs deal to buy Synthes Inc for $21.3bn, announced in April. This was reported to be the biggest purchase by JJs in its 125-year history and makes it the leader in the $5.5bn market for medical devices for treating trauma victims. At the start of the year, Sanofi finalised its takeover of Genzyme for over $20bn. This was an increased offer of $74 per share (compared to the initial bid of $69 per share) plus contingent value rights (CVRs), the value of which will depend mainly on Genzymes multiple sclerosis drug Lemtrada hitting regulatory and sales milestones. The acquisition of Genzyme brings a significant orphan drug portfolio to Sanofi. In another major transaction of 2011, announced in May, Takedas acquisition of Nycomed (excluding the Dermatological business) for $13.7bn gave Takeda extended geographical reach into Eastern European markets and Russia, where Nycomed is strong, and provides the Nycomed business with new life blood for its flagging pipeline. Just weeks before Takeda announced its move for Nycomed, Teva outbid Valeant to buy Cephalon for $6.8 billion with an increased offer of $81.50 per share. And at the end of the year was Gileads acquisition of Pharmasset and its antiviral pipeline for $11bn. An interesting financial aspect of the MA deals where the target is a public company has been the share price premium paid by the acquirer. Analysis of 15 recent acquisitions shows that the average share price premium for these transactions, excluding the Gilead deal, is 42 per cent (for example, Sanofi paid a 41 per cent premium for Genzyme, and Teva paid a 44 per cent premium for Cephalon). Most of the 15 deals assessed were for profitable companies and yet Gilead paid an eye-watering 89 per cent share price premium for Pharmasset, a company without any products on the market and making a loss. Gilead will take on $6bn of debt to fund the deal. So what is Gilead acquiring that justifies such a high price? Basically Gilead is buying a clinical pipeline of drugs for the treatment of hepatitis C. The latest stage product in the Pharmasset pipeline is an oral hepatitis C therapeutic that has recently entered phase III clinical trials; another nucleotide analogue is in phase IIb. A third hepatitis C drug in phase II is partnered with Roche. Only time will tell if the Gilead deal justified such a premium. Regional access from Rx to generics and OTC As well as Takedas acquisition of Nycomed, another example of regional access was Amgens acquisition of Bergamo in August. This purchase reflected the increasing importance that the Latin American market is having and will increasingly have, as Brazil is expected to become the fifth biggest pharmaceutical market by 2015. The numbers of generics deals were particularly high in 2011 led by Canadas Valeant and Paladin, with Teva and Par Pharmaceuticals also participating. After merging with Biovail in 2010, Valeant Pharmaceuticals was one of the most acquisition hungry companies of the year, closing transactions to acquire six companies. These exclude its failed bid to acquire Cephalon and the immediate rejection by ISTA Pharmaceuticals Board, in December 2011, to its offer of $327 million to acquire the speciality pharma company. Valeants strategy has been both in consolidating its position and expanding its geographical footprint. As part of its strategy to enhance geographic outreach, Valeant bolstered its generics portfolio through the acquisitions of PharmaSwiss with its Eastern Europe generics business for $481m and Lithuanian-based AB Sanitas for $441m, to gain a further foothold in nine Eastern European markets. Another of Valeants deals in 2011 was the $686m acquisition of Australian iNova completed in December 2011 with its Rx and OTC portfolio sold in Australia, New Zealand, Southeast Asia and South Africa. In its acquisition of the fellow Canadian OTC company Afexa Life Sciences for $76m, Valeant consolidated its position in the home OTC market. Interestingly, Afexa was wrestled from Paladin Labs as shareholders preferred Valeants offer. Paladin itself acquired Labopharm and its ailing modified release drug delivery business in August for $20m, with significant tax losses that can be offset against future profits. In 2011 we also saw significant activity not only in the numbers of deals done between Western, Chinese and Indian companies but also among China-focused companies, for example the deals between SciClone Pharma and NovaMed Pharma, and BioStar Pharmaceuticals with Shaanxi Weinan Huaren. There are said to be 5,000 pharmaceutical companies in China and it is estimated that 98 per cent of them produce generics. Therefore, not surprisingly we are also seeing an increasing level of consolidation within China as companies seek to benefit from economies of scale and to develop the profile to move outside China and participate on the global stage. As part of this evolution, Chinese companies are beginning to look at investing in, partnering and even acquiring Western companies (following the Japanese model several decades before); an example is 3SBios acquisition of EnzymeRxs pegsiticase product for development in China with the intention of developing a global product. Large pharma streamlining Another interesting feature of deals in 2011 was big pharmas quest to streamline operations. There have been a few examples of this including Pfizers $2.4bn divestment of its Capsugel Business to KKR in April, as well as its divestment of an Irish biologics manufacturing plant to Biomarin, for $48.5m. In another example of rationalisation, GSK is in the process of divesting its non-core OTC assets and in December 2011 announced that Prestige Brands Holdings was acquiring the US and Canadian rights for $660m. Perhaps the most notable streamlining activity of 2011 was Abbotts autumn announcement that it is spinning out its pharmaceutical business from the medical devices business with an $18bn price tag. This move reflects the differing visions and roadmaps seen for the two businesses. After all the mega-mergers over the last few years, it will be interesting to see if this is a trend that will emerge for other large pharma companies.2011年主要制药公司交易 2012-02-07 16:00 · 李华芸 This Deal Watch article focuses on a review of some of the trends we saw in transactions announced throughout 2011. Continuing the theme fr This Deal Watch article focuses on a review of some of the trends we saw in transactions announced throughout 2011. Continuing the theme from 2010 we saw many of the large companies addressing the need to find sources of differentiated new products, in addition to expanding into new areas such as biosimilars, generics and orphans. Interestingly and according to MedTrack data, in absolute numbers the number of deals (preclinical to pending approval) announced in 2011 was 4 per cent lower than in 2010. However, there were several deals with price tags of over $10bn. As predicted, mergers and acquisitions played a major role in continuing to change the pharmaceutical industry landscape during 2011. The rationale behind these transactions included the need to bolster flagging portfolios and buy into new therapeutic areas, as well as the extension of geographic reach. Some examples of MAs during 2011 are provided in table 1. There were some major acquisitions during the year, and one of the largest was JJs deal to buy Synthes Inc for $21.3bn, announced in April. This was reported to be the biggest purchase by JJs in its 125-year history and makes it the leader in the $5.5bn market for medical devices for treating trauma victims. At the start of the year, Sanofi finalised its takeover of Genzyme for over $20bn. This was an increased offer of $74 per share (compared to the initial bid of $69 per share) plus contingent value rights (CVRs), the value of which will depend mainly on Genzymes multiple sclerosis drug Lemtrada hitting regulatory and sales milestones. The acquisition of Genzyme brings a significant orphan drug portfolio to Sanofi. In another major transaction of 2011, announced in May, Takedas acquisition of Nycomed (excluding the Dermatological business) for $13.7bn gave Takeda extended geographical reach into Eastern European markets and Russia, where Nycomed is strong, and provides the Nycomed business with new life blood for its flagging pipeline. Just weeks before Takeda announced its move for Nycomed, Teva outbid Valeant to buy Cephalon for $6.8 billion with an increased offer of $81.50 per share. And at the end of the year was Gileads acquisition of Pharmasset and its antiviral pipeline for $11bn. An interesting financial aspect of the MA deals where the target is a public company has been the share price premium paid by the acquirer. Analysis of 15 recent acquisitions shows that the average share price premium for these transactions, excluding the Gilead deal, is 42 per cent (for example, Sanofi paid a 41 per cent premium for Genzyme, and Teva paid a 44 per cent premium for Cephalon). Most of the 15 deals assessed were for profitable companies and yet Gilead paid an eye-watering 89 per cent share price premium for Pharmasset, a company without any products on the market and making a loss. Gilead will take on $6bn of debt to fund the deal. So what is Gilead acquiring that justifies such a high price? Basically Gilead is buying a clinical pipeline of drugs for the treatment of hepatitis C. The latest stage product in the Pharmasset pipeline is an oral hepatitis C therapeutic that has recently entered phase III clinical trials; another nucleotide analogue is in phase IIb. A third hepatitis C drug in phase II is partnered with Roche. Only time will tell if the Gilead deal justified such a premium. Regional access from Rx to generics and OTC As well as Takedas acquisition of Nycomed, another example of regional access was Amgens acquisition of Bergamo in August. This purchase reflected the increasing importance that the Latin American market is having and will increasingly have, as Brazil is expected to become the fifth biggest pharmaceutical market by 2015. The numbers of generics deals were particularly high in 2011 led by Canadas Valeant and Paladin, with Teva and Par Pharmaceuticals also participating. After merging with Biovail in 2010, Valeant Pharmaceuticals was one of the most acquisition hungry companies of the year, closing transactions to acquire six companies. These exclude its failed bid to acquire Cephalon and the immediate rejection by ISTA Pharmaceuticals Board, in December 2011, to its offer of $327 million to acquire the speciality pharma company. Valeants strategy has been both in consolidating its position and expanding its geographical footprint. As part of its strategy to enhance geographic outreach, Valeant bolstered its generics portfolio through the acquisitions of PharmaSwiss with its Eastern Europe generics business for $481m and Lithuanian-based AB Sanitas for $441m, to gain a further foothold in nine Eastern European markets. Another of Valeants deals in 2011 was the $686m acquisition of Australian iNova completed in December 2011 with its Rx and OTC portfolio sold in Australia, New Zealand, Southeast Asia and South Africa. In its acquisition of the fellow Canadian OTC company Afexa Life Sciences for $76m, Valeant consolidated its position in the home OTC market. Interestingly, Afexa was wrestled from Paladin Labs as shareholders preferred Valeants offer. Paladin itself acquired Labopharm and its ailing modified release drug delivery business in August for $20m, with significant tax losses that can be offset against future profits. In 2011 we also saw significant activity not only in the numbers of deals done between Western, Chinese and Indian companies but also among China-focused companies, for example the deals between SciClone Pharma and NovaMed Pharma, and BioStar Pharmaceuticals with Shaanxi Weinan Huaren. There are said to be 5,000 pharmaceutical companies in China and it is estimated that 98 per cent of them produce generics. Therefore, not surprisingly we are also seeing an increasing level of consolidation within China as companies seek to benefit from economies of scale and to develop the profile to move outside China and participate on the global stage. As part of this evolution, Chinese companies are beginning to look at investing in, partnering and even acquiring Western companies (following the Japanese model several decades before); an example is 3SBios acquisition of EnzymeRxs pegsiticase product for development in China with the intention of developing a global product. Large pharma streamlining Another interesting feature of deals in 2011 was big pharmas quest to streamline operations. There have been a few examples of this including Pfizers $2.4bn divestment of its Capsugel Business to KKR in April, as well as its divestment of an Irish biologics manufacturing plant to Biomarin, for $48.5m. In another example of rationalisation, GSK is in the process of divesting its non-core OTC assets and in December 2011 announced that Prestige Brands Holdings was acquiring the US and Canadian rights for $660m. Perhaps the most notable streamlining activity of 2011 was Abbotts autumn announcement that it is spinning out its pharmaceutical business from the medical devices business with an $18bn price tag. This move reflects the differing visions and roadmaps seen for the two businesses. After all the mega-mergers over the last few years, it will be interesting to see if this is a trend that will emerge for other large pharma companies.我国改革开放刚刚过了30年，几年前企业界和经济学界关于中国制造向中国创造转型的呼声犹在耳畔，世界上对中国产品的信心普遍不足，在这种环境下，恒瑞医药把红旗插在FDA的山头上，肯定付出了比别人更多的努力，表现出了比别人更过硬的功夫，这是任何草根崛起必须付出的代价。

综合国力和产业发展的关系就如同公司品牌和产品品牌的关系，产业提升国力，国力促进产业。研发力量非常雄厚的齐鲁药业以前有一口号叫做国内有名、国外有声，我想对于很多即将开拓高端国际市场的企业来讲，可能先要国内有量、国外有名，以国外之名带动国内之量，以国内之量支持国外之名，以时间换市场，尽快做到国外有量。化学药的发展将随着国家富强和产业发展规律越来越好。生物药、化学药、中药是三大品类，此前和今后化学药都将是临床治疗的重要武器。

生物医药在研发上起步就比较领先，产业化上近期会有大跨越。世界医药产业即将开启中国时代 2012-02-16 16:00 · Truda 我国改革开放刚刚过了30年，几年前企业界和经济学界关于中国制造向中国创造转型的呼声犹在耳畔，世界上对中国产品的信心普遍不足，在这种环境下，恒瑞医药把红旗插在FDA的山头上，肯定付出了比别人更多的努力，表现出了比别人更过硬的功夫，这是任何草根崛起必须付出的代价。

就像中国企业赴纳斯达克上市一样，国内很多优秀的企业可能陆续叩开FDA的大门。如果没有战乱和宏观经济的大问题，二三十年后全世界将进入中医药时代北京地区开始干细胞临床研究和应用自查工作 2012-02-16 10:25 · wenmingw 2012年2月10日，北京市卫生局，北京市药品监督管理局印发文件，要求相关单位及企业开展干细胞临床研究和应用自查自纠工作。2012年2月10日，北京市卫生局，北京市药品监督管理局印发文件，要求相关单位及企业开展干细胞临床研究和应用自查自纠工作。

点击查看：关于开展北京地区干细胞临床研究和应用自查自纠工作的通知2012年2月10日，北京市卫生局，北京市药品监督管理局印发文件，要求相关单位及企业开展干细胞临床研究和应用自查自纠工作。点击查看：关于开展北京地区干细胞临床研究和应用自查自纠工作的通知。北京地区开始干细胞临床研究和应用自查工作 2012-02-16 10:25 · wenmingw 2012年2月10日，北京市卫生局，北京市药品监督管理局印发文件，要求相关单位及企业开展干细胞临床研究和应用自查自纠工作

而当银鲫的卵子与银鲫种群内极少的雄鱼精子受精时，它的卵子采用有性生殖的方式，同人类繁殖一样，生育出遗传分化了的雌性和雄性后代。他们的研究发现澄清了银鲫养殖中出现品种混杂和苗种死亡率高的原因，由此提出了银鲫苗种生产应采取单性雌核生殖方式。

今年国家自然科学奖一等奖空缺。该建议方案自2003年起已被采纳和推广。

揭开银鲫 女儿国秘密 获国家自然科学奖二等奖 2012-02-16 15:27 · tiffany 在2月14日举行的2011年度国家科技奖励大会上，中国科学院水生生物研究所研究员桂建芳团队主持完成的多倍体银鲫独特的单性和有性双重生殖方式的遗传基础研究，获得国家自然科学奖二等奖，是湖北地区唯一获得该奖项二等奖的成果。据介绍，银鲫是鲫鱼的一个品种。银鲫通常是单性雌核生殖，也就是说当它的卵子与其他鱼的精子受精时，它的卵子启动雌核生殖，生育出与母亲一模一样的全雌性后代。1995年起，在国家杰出青年科学基金等项目支持下，桂建芳团队采用克隆系间的交配和对其后代进行分子标记分析这一主要研究思路，发现银鲫具有独特的单性生殖和有性生殖双重生殖方式。在2月14日举行的2011年度国家科技奖励大会上，中国科学院水生生物研究所研究员桂建芳团队主持完成的多倍体银鲫独特的单性和有性双重生殖方式的遗传基础研究，获得国家自然科学奖二等奖，是湖北地区唯一获得该奖项二等奖的成果。银鲫很特别，其种群如同女儿国，只有1%至10%为雄性。

据全国水产技术推广总站提供的证明，其增产幅度在10%以上，每年新增效益在10亿元以上揭开银鲫 女儿国秘密 获国家自然科学奖二等奖 2012-02-16 15:27 · tiffany 在2月14日举行的2011年度国家科技奖励大会上，中国科学院水生生物研究所研究员桂建芳团队主持完成的多倍体银鲫独特的单性和有性双重生殖方式的遗传基础研究，获得国家自然科学奖二等奖，是湖北地区唯一获得该奖项二等奖的成果。

据介绍，银鲫是鲫鱼的一个品种。在2月14日举行的2011年度国家科技奖励大会上，中国科学院水生生物研究所研究员桂建芳团队主持完成的多倍体银鲫独特的单性和有性双重生殖方式的遗传基础研究，获得国家自然科学奖二等奖，是湖北地区唯一获得该奖项二等奖的成果。

今年国家自然科学奖一等奖空缺。他们的研究发现澄清了银鲫养殖中出现品种混杂和苗种死亡率高的原因，由此提出了银鲫苗种生产应采取单性雌核生殖方式。

该建议方案自2003年起已被采纳和推广。据全国水产技术推广总站提供的证明，其增产幅度在10%以上，每年新增效益在10亿元以上。银鲫通常是单性雌核生殖，也就是说当它的卵子与其他鱼的精子受精时，它的卵子启动雌核生殖，生育出与母亲一模一样的全雌性后代。而当银鲫的卵子与银鲫种群内极少的雄鱼精子受精时，它的卵子采用有性生殖的方式，同人类繁殖一样，生育出遗传分化了的雌性和雄性后代。

银鲫很特别，其种群如同女儿国，只有1%至10%为雄性。1995年起，在国家杰出青年科学基金等项目支持下，桂建芳团队采用克隆系间的交配和对其后代进行分子标记分析这一主要研究思路，发现银鲫具有独特的单性生殖和有性生殖双重生殖方式

Illumina公司部分股东向这家生命科学公司提出集体诉讼，指控其董事会根据高盛的坏建议下，通过了一项毒丸计划阻止由瑞士制药商罗氏控股有限公司的收购。Illumina曾启动毒丸计划对抗罗氏的收购 诉讼于星期二在特拉华州法院提交，代表所有Illumina公司股东利益。

罗氏公司女发言人也没有立即发表评论。原告称高盛建议Illumina拒绝罗氏公司57亿美元的收购要约，并建议该公司采取毒丸计划的防御战略。

该诉讼称，Illumina公司莫名其妙地选择接受高盛的意见，即使是与广大股东利益相冲突。部分股东就毒丸计划集体起诉Illumina公司 2012-02-16 11:00 · lule Illumina公司部分股东向这家生命科学公司提出集体诉讼，指控其董事会根据高盛的坏建议下，通过了一项毒丸计划阻止由瑞士制药商罗氏控股有限公司的收购。该诉讼声称，由于Illumina公司和高盛之间存在一个复杂的衍生工具交易，如果罗氏的提议被接受，高盛将面临数以亿计的损失， Illumina公司和高盛发言人拒绝对此发表评论应该说，这对我们影响不大。

肿瘤领域拓展是安斯泰来锁定的第三个全球专业治疗领域。不过，黑田昌利认为，新医改着眼于将国家投入重点由药剂向医疗转移，着力点在降低药品成本，这给药企经营本身带来很大的挑战。

从2010财年来看，中国地区的销售正以超过20%的速度飞速增长，占整个亚太地区(除日本以外)销售总额的40%。十二五规划对创新药物的大力支持以及新医改的全面实施，为以研发为基础的创新型制药企业带来了新机遇。

这一发展战略给安斯泰来提供了不菲业绩：凭借普乐可复和哈乐两大支柱产品在全球市场的优异表现，奠定其在器官移植与泌尿两个领域的全球领导地位。基本药物制度的推行确实降低了用药成本，不过进入药品报销目录的药品种类和范围受到了不小的限制，特别是各地采取了以压价为主要目标的招标采购政策，令众多品牌药企叫苦不迭。